Haruki Kobayashi
Overview
Explore the profile of Haruki Kobayashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
454
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishibori Y, Kenmotsu H, Ando K, Tonsho A, Matsuda S, Morita M, et al.
Cancer Treat Res Commun
. 2024 Nov;
41:100849.
PMID: 39536390
Objectives: The current standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiation therapy (CCRT) followed by durvalumab consolidation therapy. Although the trial revealed the survival benefit...
2.
Kobayashi H, Naito T
Thorac Cancer
. 2024 Oct;
15(34):2456-2457.
PMID: 39446593
No abstract available.
3.
Morita M, Ono A, Sekikawa M, Doshita K, Miura K, Kodama H, et al.
Cancer Rep (Hoboken)
. 2024 Sep;
7(9):e70004.
PMID: 39245880
Background: Mutations in the epidermal growth factor receptor (EGFR) gene are the most common targetable gene alterations in non-small cell lung cancer (NSCLC). In Japan, approximately 40% of patients who...
4.
Liu Q, Qin C, Wan J, Mai B, Sui X, Kobayashi H, et al.
J Am Chem Soc
. 2024 Jul;
146(32):22485-22497.
PMID: 39078367
Stereochemically defined organofluorine compounds are central to drug discovery and development. Here, we present a catalytic cross-metathesis method for the synthesis of -trisubstituted olefins that contain a Cl- and a...
5.
Doshita K, Naito T, Matsuda S, Morita M, Sekikawa M, Miura K, et al.
Thorac Cancer
. 2024 Jul;
15(25):1831-1841.
PMID: 39075850
Background: Chemotherapy-induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy-induced anorexia and weight loss during platinum-based chemotherapy combined with immune...
6.
Morikawa N, Naito T, Morita M, Sekikawa M, Doshita K, Yabe M, et al.
J Geriatr Oncol
. 2024 Jul;
15(7):101832.
PMID: 38997933
Introduction: The effect of polypharmacy on older patients with cancer is unclear. This study aimed to explore the effect of polypharmacy on the outcomes of treatment in older patients with...
7.
Kobayashi H
BMC Pulm Med
. 2024 Jun;
24(1):299.
PMID: 38918749
The efficacy of immune checkpoint inhibitors (ICIs) has been widely recognized in several cancers and is now being used in the perioperative setting for lung cancer.We recently encountered an immune-related...
8.
Kodama H, Murakami H, Mamesaya N, Kobayashi H, Omori S, Wakuda K, et al.
Thorac Cancer
. 2024 Jun;
15(21):1665-1672.
PMID: 38898747
Background: The AmoyDx Pan lung cancer PCR panel (AmoyDx PLC panel) has been approved as a companion diagnostic tool for multiple anticancer agents in patients with non-small cell lung cancer...
9.
Ando K, Naito T, Hamauchi S, Miura K, Nishibori Y, Tonsho A, et al.
Int J Clin Oncol
. 2024 May;
29(8):1115-1121.
PMID: 38722487
Background: Anamorelin is a selective ghrelin receptor agonist approved for cancer cachexia in Japan. Little is known about predictors of anamorelin efficacy. This study aimed to assess the effect of...
10.
Iida Y, Wakuda K, Kenmotsu H, Doshita K, Kodama H, Nishioka N, et al.
Sci Rep
. 2024 Apr;
14(1):7641.
PMID: 38561461
The efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma (LCNEC) is unclear. This study aimed to evaluate the efficacy of second-line chemotherapy in patients with pulmonary...